Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating)’s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.
Adaptimmune Therapeutics Stock Up 19.6 %
The company’s 50 day moving average price is $1.71 and its 200 day moving average price is $2.04. The firm has a market capitalization of $375.88 million, a price-to-earnings ratio of -2.15 and a beta of 1.79.
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06). Adaptimmune Therapeutics had a negative return on equity of 76.84% and a negative net margin of 1,836.31%. The company had revenue of $3.58 million for the quarter, compared to analyst estimates of $4.00 million. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. As a group, analysts expect that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current year.
Institutional Inflows and Outflows
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- These Are The Top Insider Buying Stocks For July
- Time To Take A Serious Look At Nikola Stock As Production Starts
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.